Phase II trial of aminothiadiazole in previously treated and untreated patients with advanced colorectal carcinoma: An Illinois Cancer Council trial

G. Y. Locker; J. Khandekar; S. Krauss; H. Reisel; T. Hoeltgen; J. Wolter; M. Haid; R. Hoffman; R. Blough; C. Johnson

Phase II trial of aminothiadiazole in previously treated and untreated patients with advanced colorectal carcinoma: An Illinois Cancer Council trial

G. Y. Locker, J. Khandekar, S. Krauss, H. Reisel, T. Hoeltgen, J. Wolter, M. Haid, R. Hoffman, R. Blough, C. Johnson

Diagnostic Radiology

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Eighty-three patients with advanced colorectal carcinoma were entered on a phase II trial of weekly iv aminothiadiazole (125 mg/m²) plus daily oral allopurinol (300 mg). There were five partial responses. Median survival of all patients on study was 36 weeks from entry (48 weeks for those without prior therapy and 34 weeks for those with previous chemotherapy). Toxicity was generally mild and consisted predominantly of stomatitis. In the dose given, aminothiadiazole has limited activity against metastatic colorectal cancer.

Original language	English (US)
Pages (from-to)	649-650
Number of pages	2
Journal	Cancer Treatment Reports
Volume	71
Issue number	6
State	Published - 1987

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

@article{d36924734d86432a9eb4411799f8cab2,

title = "Phase II trial of aminothiadiazole in previously treated and untreated patients with advanced colorectal carcinoma: An Illinois Cancer Council trial",

abstract = "Eighty-three patients with advanced colorectal carcinoma were entered on a phase II trial of weekly iv aminothiadiazole (125 mg/m2) plus daily oral allopurinol (300 mg). There were five partial responses. Median survival of all patients on study was 36 weeks from entry (48 weeks for those without prior therapy and 34 weeks for those with previous chemotherapy). Toxicity was generally mild and consisted predominantly of stomatitis. In the dose given, aminothiadiazole has limited activity against metastatic colorectal cancer.",

author = "Locker, {G. Y.} and J. Khandekar and S. Krauss and H. Reisel and T. Hoeltgen and J. Wolter and M. Haid and R. Hoffman and R. Blough and C. Johnson",

year = "1987",

language = "English (US)",

volume = "71",

pages = "649--650",

journal = "Cancer Treatment Reports",

issn = "0361-5960",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Phase II trial of aminothiadiazole in previously treated and untreated patients with advanced colorectal carcinoma

T2 - An Illinois Cancer Council trial

AU - Locker, G. Y.

AU - Khandekar, J.

AU - Krauss, S.

AU - Reisel, H.

AU - Hoeltgen, T.

AU - Wolter, J.

AU - Haid, M.

AU - Hoffman, R.

AU - Blough, R.

AU - Johnson, C.

PY - 1987

Y1 - 1987

N2 - Eighty-three patients with advanced colorectal carcinoma were entered on a phase II trial of weekly iv aminothiadiazole (125 mg/m2) plus daily oral allopurinol (300 mg). There were five partial responses. Median survival of all patients on study was 36 weeks from entry (48 weeks for those without prior therapy and 34 weeks for those with previous chemotherapy). Toxicity was generally mild and consisted predominantly of stomatitis. In the dose given, aminothiadiazole has limited activity against metastatic colorectal cancer.

AB - Eighty-three patients with advanced colorectal carcinoma were entered on a phase II trial of weekly iv aminothiadiazole (125 mg/m2) plus daily oral allopurinol (300 mg). There were five partial responses. Median survival of all patients on study was 36 weeks from entry (48 weeks for those without prior therapy and 34 weeks for those with previous chemotherapy). Toxicity was generally mild and consisted predominantly of stomatitis. In the dose given, aminothiadiazole has limited activity against metastatic colorectal cancer.

UR - http://www.scopus.com/inward/record.url?scp=0023188843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023188843&partnerID=8YFLogxK

M3 - Article

C2 - 3555791

AN - SCOPUS:0023188843

SN - 0361-5960

VL - 71

SP - 649

EP - 650

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

IS - 6

ER -

Phase II trial of aminothiadiazole in previously treated and untreated patients with advanced colorectal carcinoma: An Illinois Cancer Council trial

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this